Brad Bostic, CEO, hc1 The fundamental problem with healthcare can be summed up in one sentence: We expect healthcare services that cater to our individual needs, yet the health care system operates under a one-size-fits-all, trial-and-error model. It is a model that results in missed… Read More »PHINs: Addressing the Fundamental Flaws that Have Broken Healthcare
What You Should Know: – Today, Deep Lens and Cardinal Health announced a strategic collaboration that will integrate Deep Lens’ AI-based clinical trial matching solution, VIPER, into community-based oncology practices throughout the Cardinal network. VIPER will be a part of Cardinal Health’s new Navista advanced… Read More »Cardinal Health and Deep Lens Collaborate for AI-based Oncology Clinical Trial Matching
Kenya Smith, Healthcare Solution Marketing Manager at ABBYY AI technology is quickly evolving and already surpassing human decision-making in certain instances; sometimes, in ways, we can’t explain. While many are alarmed by this, AI is producing some of the most effective and dramatic results in… Read More »3 Barriers Stalling AI Adoption in Revenue Cycle Management
Dr. Miller, Medical Director of CancerLinQ LLC Despite decades of scientific progress against cancer, access to treatment remains highly unequal. Some of the reasons — like institutional racism and poverty — are a reflection of our broader society. Other inequities may go unrecognized but are… Read More »To Advance Health Equity, Put Real-World Cancer Data to Work
What You Should Know: – AppliedVR, a Los Angeles, CA-based company advancing the next generation of digital medicine, today announced $29 million in Series A funding, bringing its total funds raised to date to $35 million. The round, which includes key investors F-Prime Capital, JAZZ… Read More »AppliedVR Lands $29M for VR Platform to Treat Chronic Pain
NLP and social graphs are effective instruments to speed up investigator recruitment and ensure timely pharmaceutical product releases. Read how NLP can leverage the power of unstructured data and help find doctors-influencers that can substantially provide assistance to a clinical trial. Igor Kruglyak is a… Read More »Accelerating Investigator Recruitment with NLP
Kroger Health Partners with Gauss to Provide Smartphone-Enabled COVID-19 Rapid Antigen Home Tests What You Should Know: – Kroger Health, the healthcare division of The Kroger Co. announced plans to offer the first smartphone-enabled, at-home Gauss COVID-19 Rapid Antigen Test Kit to patients nationwide, expanding… Read More »Kroger Health to Offer Smartphone-Enabled COVID-19 Tests Nationwide
Shots: The P-II/III study involves assessing of CT-P59 (40mg/kg, 80mg/kg) vs PBO in 327 patients with mild-to-mod. symptoms of COVID-19 Results: reduction in progression rates (54% for mild-to-mod. patients & 68% for mod. patients aged ≥50yrs.); recovery days (5.4 vs 8.8 days); recovery time in… Read More »Celltrion Report Results of CT-P59 in P-II/III Study for COVID-19
Dr. Brandon Salke, PHARM.D, Pharmacist-in-charge, Optime Care One of the biggest challenges for biopharmaceutical companies of rare and orphan disease patient populations is optimizing disease management in a way that enhances the patient journey and improves outcomes. As these companies seek innovative solution partners, a… Read More »Why A Patient-First Strategy for Specialty Rx Pharmacists Is Critical to Optimize Outcomes
Shots: Tiziana has completed its clinical study in Brazil assessing nasally administered Foralumab either alone or in combination with orally administered dexamethasone in COVID-19 patients The study enrolled 39 patients with mod. to sev. COVID-19 who did not require the use of a ventilator at… Read More »Tiziana Completes Clinical Trial of Nasally Administered Foralumab for COVID-19 in Brazil
As we close out the year, we asked several healthcare executives to share their predictions and trends for 2021. Kimberly Powell, Vice President & General Manager, NVIDIA Healthcare Federated Learning: The clinical community will increase their use of federated learning approaches to build robust AI models across various… Read More »30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021
What You Should Know: – Philips and BioIntelliSense has been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to receive nearly $2.8M from the U.S. Department of Defense (DoD) to validate BioIntelliSense’s FDA-cleared BioSticker device for the early detection of COVID-19 symptoms.… Read More »DoD Awards $2.8M to Philips & BioIntelliSense to Validate Wearable for Early COVID-19 Detection
AstraZeneca and Amgen looked on course to cruise to approval of their severe asthma drug tezepelumab with a pair of positive clinical trials, but the failure of a third threatens to derail the programme. The new study – called SOURCE – was supposed to back… Read More »AZ, Amgen’s asthma hope tezepelumab flunks phase 3 trial
What You Should Know: – H1, the largest database of information on every doctor in the world raises $58M in Series B funding, just six months after raising its Series A round during the pandemic. – H1 is the largest database in the world connecting… Read More »H1 Secures $58M to Expand Global Healthcare Data Platform
What You Should Know: – Cerner announces it will acquire Kantar Health, a leading data, analytics, and real-world evidence and commercial research consultancy serving the life science and health care industry. – This acquisition is expected to allow Cerner’s Learning Health Network client consortium and… Read More »M&A: Cerner to Acquire Health Division of Kantar for $375M in Cash
What You Should Know: – Lightspeed Venture Partners, the VC behind Nest and GrubHub, is leading a $10 million round for Freespira, an FDA-cleared digital therapeutic proven to significantly reduce or eliminate panic attacks and PTSD symptoms by training users to normalize respiratory irregularities. –… Read More »Freespira Secures $10M for FDA-Cleared Digital Therapeutic to Eliminate Panic Attacks, PTSD Symptoms
What You Should Know: – Cerner announced a strategic investment in Elligo Health Research, a leading research organization that enables clinical trials with nationwide community-based health care practices. – Cerner plans to expand the data and tools available in the Cerner Learning Health Network to… Read More »Cerner Invests in Elligo to Make Clinical Trials Accessible for Health Systems of All Sizes
What You Should Know: – Ro announced it has acquired Workpath, a technology platform that powers on-demand, in-home healthcare and diagnostics services nationwide. – Through this acquisition, Ro’s platform will now uniquely bring together a patient’s doctor, pharmacy, and diagnostics/lab–offering a personalized, end-to-end experience with… Read More »M&A: Ro Acquires On-Demand, In-Home Platform Workpath
David Talby, CTO, John Snow Labs Each year, Adverse Drug Events (ADE) account for nearly 700,000 emergency department visits and 100,000 hospitalizations in the US alone. Nearly 5 percent of hospitalized patients experience an ADE, making them one of the most common types of inpatient… Read More »NLP is Raising the Bar on Accurate Detection of Adverse Drug Events
Shots: The companies initiated the P-II study of their COVID-19 vaccine in China. The trial will generate data to support the BLA filing for approval of the vaccine in China The study will be conducted by Jiangsu Provincial Center for Disease Control and Prevention. The… Read More »BioNTech and Fosun Pharma Initiate P-ll Study of BNT162b2 Against COVID-19 in China
Neela Montgomery, EVP & President at CVS Pharmacy/Retail CVS Health Corporation names Neela Montgomery Executive Vice President and President of CVS Pharmacy/Retail, effective November 30, 2020. Montgomery will oversee the company’s 10,000 pharmacies across the United States. Montgomery, currently a Board Partner at venture capital… Read More »Recent Executive Hires: CVS Health New President, Cleveland Clinic/Amwell Joint Venture Leadership, Others
Just over a year after its first phase 3 trial of its Engensis gene therapy for painful diabetic peripheral neuropathy (DPN) bombed, Helixmith has started dosing patients in a new study. The South Korean biotech says the DNA plasmid-based therapy has been administered to a… Read More »Helixmith starts new trial of diabetic neuropathy gene therapy
What You Should Know: – New study out from Propeller and Chicago’s NorthShore University HealthSystem shows that asthma patients maintain higher medication adherence and decrease their rescue inhaler use when using a digital health platform. – The study looked at 100 patients recruited from NorthShore… Read More »Study: Asthma Patients Maintain High Medication Adherence Using Propeller Health’s Platform
CMS will cover monoclonal antibody treatments for Medicare beneficiaries with Covid-19. Though this is a step forward in increasing access to these treatments, there are still hurdles to its widespread use.
Shots: J&J has resumed recruitment, enrolment, and vaccination in all studies of its COVID-19 vaccine across the EU, after a temporary pause. Trials in the US, South Africa, and some Latin American countries are already ongoing Clinical trials to be resumed are the P-IIa studies… Read More »J&J Resumes all Clinical Trial of its COVID-19 Vaccine in the EU
What You Should Know: – The FDA just extended its research collaboration agreement (RCA) with COTA, specifically looking at how COVID-19 is affecting cancer. – With this expanded agreement, COTA and the FDA will use real-world data to explore the impact of COVID-19 and the… Read More »FDA Extends RCA With COTA to Explore COVID’s Effect on Cancer
The digital health startup released the results of a 599-person randomized clinical trial on Tuesday. It found a statistically significant reduction in participants’ weight and hemoglobin A1c levels.
What You Should Know: – FDA awards AppliedVR Breakthrough Device designation for treating treatment-resistant fibromyalgia and chronic intractable lower back pain – AppliedVR’s EaseVRx program helps patients learn self-management skills grounded in evidence-based cognitive-behavioral therapy (CBT) principles and other behavioral methods. AppliedVR, a pioneer advancing… Read More »FDA Grants AppliedVR Breakthrough Designation for Virtual Reality Chronic Pain Treatment
Shots: The P-II ROCCELLA is a dose-ranging trial involves assessing GLPG1972/S201086 (PO, qd) in three different doses vs PBO in 932 patients with knee OA for 52wks. across 12 countries including EU, Asia, North and South America. Galapagos is responsible for ROCCELLA in the US,… Read More »Galapagos & Servier’s GLPG1972/S201086 Fails to Meet its Primary Endpoint in P-II ROCCELLA Study for Knee Osteoarthritis
What You Should Know: – Virta is expanding its suite of treatment options to include prediabetes reversal, obesity reversal, and type 2 diabetes management. – By making this crucial expansion, Virta can scale its treatment to support the tens of millions of additional patients with… Read More »Virta Expands Offerings to Treat New Group of Chronic Illnesses
Shots: The multiple expansion cohort will assess the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors harboring a KRAS G12C mutation Strata Oncology will identify patients to be considered for enrollment into Mirati’s P-I/II study. The… Read More »Strata Oncology Collaborates with Mirati Therapeutics to Broaden Enrollment in Clinical Trial of MRTX849 for Patients with Advanced Solid Tumors
Shots: The P-I study will evaluate the safety and immunogenicity of the vaccine as well as confirm dose selection in ~144 healthy subjects aged 18-55 and >55 yrs. As part of the two-dose cohort design, subjects will receive two injections (prime-boost), 21 days apart BNT162b1… Read More »BioNTech and Fosun Pharma Initiate Clinical Trial of BNT162b1 Against COVID-19 in China
First dose of ETC-159 administered in Phase 1B of clinical trials, advancing the development of this drug to treat solid tumours Made-in-Singapore cancer drug, ETC-159, has achieved a new developmental milestone in achieving “First Patient First Visit[1]” in Phase 1B. The first dose of ETC-159… Read More »Made-in-Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials
An app combining physical therapy, relaxation exercises and medical education developed by Kaia Health has been shown to improve physical and mental symptoms in people with chronic lower back pain. The iOS and Android app was put through its paces in a 1,245-patient study reported… Read More »Kaia app for lower back pain shows its worth in large-scale trial
France’s Genfit has said its elafibranor drug as a treatment for non-alcoholic steatohepatitis (NASH) was unable to improve patient outcomes in a phase 3 study, which has now been terminated. Genfit took the “highly disappointing” decision after taking a look at interim data from the… Read More »Genfit abandons late-stage trial of NASH drug elafibranor
Data from more than 1,000 healthy volunteers dosed with a coronavirus vaccine developed at Oxford University and AstraZeneca suggest the shot is safe and stimulates an immune response against the virus. The first phase 1/2 results with the ChAdOx1 vaccine – also known as AZD122… Read More »‘Promising’ data on Oxford/AZ, CanSino coronavirus vaccines
What You Should Know: – Paige secures an additional $15M from Goldman Sachs for a total Series B funding round of $70M for its AI-native digital pathology ecosystem. – The company’s continued product portfolio of innovation in telepathology and digital diagnostics accelerated by further investment.… Read More »Paige Lands Additional $15M for AI-Native Digital Pathology Ecosystem
What You Should Know: – The COVID-19 crisis has significantly impacted the patient care paradigm, and the ripple effects have altered patient behaviors and expectations, requiring a significant change in how life sciences companies engage with and support patients – Accenture surveyed 2700 patients about… Read More »COVID-19 Has Permanently Shifted Patient Behavior Towards Virtual Care
What You Should Know: – Repurpose.AI, has partnered with Scripps Research to discover drug candidates that may be repurposed to treat COVID-19. – The partnership will leverage Repurpose.AI’s ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, to discover… Read More »Scripps Research, Repurpose.AI Partner to Develop COVID-19 Therapeutics
Shots: The second P-III LIBRETTO-531 involves assessing of selpercatinib vs physician’s choice of cabozantinib or vandetanib in 400 patients in ratio (2:1) with advanced or metastatic RET-mutant MTC who have received no prior systemic therapy for metastatic disease The study will have efficacy endpoints as… Read More »Eli Lilly Opens its P-III LIBRETTO-531 Clinical Trial for LOXO-292 (selpercatinib) to Treat RET-Mutant Medullary Thyroid Cancer (MTC) Patients